The biological function as well as gene expression of the MRP/GS-X pump is closely linked with cellular GSH metabolism. This article describes two important aspects, i.e., 1) a role of the MRP/GS-X pump in the modulation of cell cycle arrest induced by anticancer prostaglandins; 2) coordinated up-regulation of γ -glutamylcysteine synthetase (γ -GCS) and MRP1 genes. The A and J series of prostaglandins (PGs) accumulate in the nuclei to suppress the proliferation of cancer cells. 7 -Prostaglandin A 1 ( 7 -PGA 1 ) methyl ester, a synthetic anticancer PG, increased the mRNA level of the cyclin-dependent kinase inhibitor p21 Sdi1/CI P 1/W AF 1 in human leukemia HL-60 cells. The induction of p21 Sdi1/CI P 1/W AF 1 was associated with the accumulation of hypophosphorylated retinoblastoma protein (pRB) and the suppression of c-myc gene expression. Unlike HL-60 cells, cisplatin-resistant HL-60/R-CP cells were insensitive to 7 -PGA 1 methyl ester. While c-myc expression was transiently suppressed, neither G1 arrest nor hypophosphorylation of pRB was observed with the anticancer PG. Plasma membrane vesicles from HL-60/R-CP cells showed an enhanced level of GS-X pump activity toward the glutathione Sconjugate of 7 -PGA 1 methyl ester. GIF-0019, a potent inhibitor of the GS-X pump, dose-dependently enhanced the cellular sensitivity of HL-60/R-CP cells to 7 -PGA 1 methyl ester, resulting in G1 arrest. The GS-X pump is suggested to play a pivotal role in modulating the biological action of the anticancer PG. The expression of MRP1 and γ -GCS genes can be coordinately up-regulated by cisplatin, 1-[5-(4-amino-2-methyl)pyrimidyl]methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU), and heavy metals in human cancer cells. For the up-regulation of these genes, both transcriptional and posttranscriptional regulations are considered to be involved.
Introduction
Drug resistance is a biological response of tumor cells to antitumor agents, representing a constitution of different biochemical and genetic determinants. Identification and modulation of such determinants are important for understanding the biological nature of drug resistance and solving the associated problems in human cancer chemotherapy. Recent studies on the multidrug resistance phenotype of tumor cells have led to the discovery of two different types of ATP-binding cassette (ABC) transporters, i.e., Pglycoprotein (MDR) (Gottesman and Pastan, 1988; Endicott and Ling, 1989) and multidug resistanceassociated protein (MRP) (Cole et al., 1992; Zaman et al., 1994) , that mediate the efflux of certain anticancer drugs from cells. The overexpression of one of these export pumps in tumor cells in vitro has been shown to be closely associated with certain multidrug resistance phenotypes. The substrate specificities of P-glycoprotein and MRP appears to be different. While the exact mechanisms of MRP-mediated drug resistance remain to be determined, many recent studies strongly suggest that MRP may transport a wide range of organic anions, including glutathione disulfide (GSSG), glutathione-metal complexes, glutathione conjugates, cysteinyl leukotrienes as well as glucuronate and sulfate conjugates (Müller et al., 1994; Leier et al., 1994; Jedlitschuky et al., 1996; Loe et al., 1996a, b) . These findings are consistent with the idea that the MRP gene product is the previously descrived GS-X pump, a member of the phase III drug metabolizing system (Ishikawa, 1992) .
The fact that the MRP1 gene encodes a human GS-X pump supports an important scenario that glutathione (GSH) metabolism may play a pivotal role in overall MRP-mediated drug resistance. Accumulating evidence suggests that GSH-mediated drug metabolism and disposition are major mechanisms of tumor drug resistance. It has been reported that depletion of intracellular GSH by buthionine sulfoximine (BSO) resulted in a complete reversal of drug resistance in MRP1 cDNA-transfected lung carcinoma cells (Zaman et al., 1995) . ATP-dependent transport of certain anticancer drugs, e.g. vincristine, can be enhanced by the presence of GSH in membrane vesicles prepared from MRP1-overexpressing cells (Loe et al., 1996a) . Furthermore, we have demonstrated increases of intracellular GSH level in the MRP1-overexpressing human cisplatin-resistant HL-60 leukemia cell line, HL-60/R-CP (Ishikawa et al., 1994) . Steady state levels of MRP1 and γ -GCS catalytic heavy subunit mRNA were found to be elevated in HL-60/R-CP cells as compared to those in the parental HL-60 cells . Coordinated overexpression of these genes frequently occurs in human colorectal cancers . Likewise, a coordinated increase of MRP1 and γ -GCS mRNA was also observed in ethacrynic acid-resistant HT29 human colon cancer cells (Ciaccio, 1996) . These observations strongly suggest that the biological function of the GS-X pump encoded by the MRP1 gene is closely linked with cellular GSH metabolism.
This review article presents a new aspect on the role of the GS-X pump encoded by the MRP1 gene in GSH-associated drug resistance of cancer cell, in particular, the modulation of cell cycle arrest induced by anticancer prostaglandins (PGs) that has most recently been studied in our laboratory. In addition, we will discuss transcriptional and posttranscriptional regulations as potential molecular mechanisms involved in the induction of the MRP/GS-X pump.
GS-X Pump Family
Cancer cells, as well as normal cells in animals and plants, eliminate a broad range of lipophilic toxins from the cytosol after their conjugation with GSH (Ishikawa, 1992; Martinoia et al., 1993; Li et al., 1995) . This transport process is mediated by a GS-X pump, an organic anion-transporting Mg 2+ -ATPase. The term of 'GS-X pump' was originally proposed based on its transport activity and high affinity toward glutathione S-conjugates (GS-conjugates), GSSG, and cysteinyl leukotrienes (Ishikawa, 1992) . The kinetic properties and substrate specificity of the GS-X pump have been intensively studied using plasma membrane vesicles from different biological sources. The GS-X pump has a broad substrate specificity toward different types of organic anions and thereby plays a physiologically important role in inflammation, oxidative stress, xenobiotics metabolism, and tumor drug resistance. In plants, the GS-X pump is competent in the transport of GS-conjugates of the chloroacetanilide and triazine herbicides, metolachlor and simetryn, respectively, as well as GSSG and GS-conjugates of 1-chloro-2,4-dinitrobenzene (CDNB) and monochlorobimane (Martinoia et al., 1993; Li et al., 1995) . It has recently been suggested that the GS-X pump is involved in the anthocyanin biosynthetic pathway (Marrs et al., 1995) .
During past five years, there was a remarkable progress in our understanding of the molecular nature of the GS-X pumps. Overexpression of the MRP1 gene in human cancer cells has been first reported to result in increased ATP-dependent GS-conjugate transport, thus demonstrating that the MRP1 gene encodes a human GS-X pump (Müller et al., 1994; Leier et al., 1994) . A liver specific GS-X pump, named cMOAT, has also been cloned from rat liver cDNA libraries and it exhibited an extensive homology with human MRP1 (Paulusma et al., 1996; Büchler et al., 1996; Ito et al., 1997) . Mutation of the cMOAT gene is implicated to be a cause of hereditary hyperbilirubinemia associated with defective function of the hepatic GS-X pump. The yeast cadmium factor (YCF1) gene from Saccharomyces cerevisiae has been identified on the basis of its ability to confer cadmium resistance (Szczypka et al., 1994) . The YCF1 gene encodes an ABC protein homologous to human MRP1, and the protein has recently been identified as a vacuolar GS-X pump in yeast cells (Li et al., 1996) . Furthermore, two cDNAs, i.e. AtMRP1 and AtMRP2, encoding GS-X pump in a plant Arabidopsis thaliana have been cloned and they Figure 1 . Schematic illustration of the biosynthesis of GSH, conjugation of GSH with electrophilic drugs (X), inhibition of GSH transferase by GSH conjugate (GS-X), and ATP-dependent export of GS-X from cells via the GS-X pump. also show extensive sequence homologies to MRP1, cMOAT and YCF1 . GS-X pumps comprise a multigene family in both the animal and plant kingdoms Keppler and König, 1997; Kool et al., 1997) .
GS-X Pump and GSH Metabolism
The function of the GS-X pump is closely linked with cellular GSH metabolism. Glutathionation provides negative charges to compounds and thereby enables the substrate recognition by the GS-X pump. GSH bears two important features in the structure, namely, the γ -glutamate linkage and the SH-group, both of which are intimately linked to its intracellular stability and biological functions. The intracellular concentration of GSH in mammalian cells is 1-10 mM, which is even higher than the intracellular concentration of ATP. In many cells, GSH accounts for more than 90% of the total nonprotein sulfur. Such high intracellular concentration of GSH is made possible by the γ -Glu linkage structure, which protects the GSH molecule from protease cleavage. The SHgroup of GSH is strongly nucleophilic and confers to the molecule the unique ability to react with a wide variety of agents including free radicals, reactive oxygen species, heavy metals, and cytotoxic electrophilic compounds, thereby playing a critical role of detoxification in living cells.
The biosynthesis of GSH takes place in the cytosol. The reaction consists of two steps catalyzed by γ -glutamylcysteine synthetase and by GSH synthetase, where each step requires one molecule of ATP (Figure 1) . γ -GCS catalyzes the first step (Reaction 1) in which an amide linkage is formed between the amino group of cysteine and the γ -carboxyl group of glutamate. In the second step, GSH synthetase catalyzes the reaction between glycine and the cysteine carboxyl group of γ -glutamylcysteine:
The reaction catalyzed by γ -GCS is the rate-limiting step of GSH biosynthesis and is controlled by negative feedback from its end product, GSH, via nonallosteric competitive inhibition. As described below, coordinated up-regulation of the γ -GCS gene together with the MRP1/GS-X pump gene has been frequently observed in many of human cancer cells.
The pathway of GSH-mediated drug inactivation is a biologically 'expensive' mechanism. The synthesis of GSH and the export of GS-conjugates from the cytosol require at least three molecules of ATP in order to metabolize 1 mol of the drug molecule. This compares unfavorably with the glycolytic pathway, in which only two molecules of ATP are gained from one molecule of glucose. Nevertheless, the fact that the GS-X pump is ubiquitously distributed in the plant and animal kingdoms strongly suggests that the GSH-associated metabolism and transport pathway are fundamentally important for the survival of living cells. 
Anticancer Prostaglandins and their Biological Action
Regulation of cell growth and proliferation is of fundamental biological interest. We here provide evidence that GSH and the GS-X pump are critically involved in the modulation of cell cycle arrest induced by anticancer prostaglandins (PGs). Accumulating evidence suggests that arachidonic acid and its metabolites constitute a novel class of intracellular second messengers. Of the different types of PGs, the A and J series PGs are unique in exerting their biological activity via direct interaction with putative nuclear proteins rather than with plasma membrane receptors. The A and J series of PG (PGA and PGJ) suppress proliferation of tumor cells in vivo as well as in vitro without affecting intracellular cAMP levels (Narumiya and Fukushima, 1989) . These antitumor PGs are actively transported into tumor cells and their nuclear accumulation correlates closely with cell growth inhibition and cell-cycle arrest in the G1 phase (Ohno et al., 1988) . The significance of anticancer PGs as novel biochemical probes has been strengthened by a newly developed method called the 'three-component coupling synthesis', which has made it possible to generate large quantities of structurally modified PGs (Suzuki et al., 1990; Noyori and Suzuki, 1993) . 7 -PGA 1 methyl ester, a synthetic antitumor PG, exhibits remarkable biological properties. At a concentration of 1.5 µM, it suppressed the proliferation of HL-60 cells by 50%, 3-to 5-fold more effectively than PGA 2 , a natural antitumor PG. 5 µM 7 -PGA 1 methyl ester suppressed the proliferation of HL-60 cells over 100 h (Figure 2 ), where the cell cycle was blocked in G1 phase. c-myc mRNA level decreased within 2 h and the suppression of c-myc expression lasted over 36 h (Figure 3 ; Akimaru et al., 1996) . The inhibition of cell proliferation, cell-cycle arrest, and suppression of c-myc gene expression were closely related to accumulation of hypophosphorylated retinoblastoma gene product (pRB) (Figure 4 ). pRB plays a critical role in cell-cycle progression by virtue of its potency of inhibiting the activity of the E2F family of transcription factors for c-myc, Bmyb, dihydrofolate reductase, and DNA polymerase α. Figure 4 . Effect of 7 -PGA 1 methyl ester on the phosphorylation state of pRB. HL-60 and HL-60/R-CP cells were incubated with 5 µM 7 -PGA 1 methyl ester. pRB was detected by western blotting using pRB-specific antibody. Figure 5 . Effect of 7 -PGA 1 methyl ester on the expression of p21 in HL-60 cells. Cells were treated with 5 µM 7 -PGA 1 methyl ester for the specified time periods (0, 1, 3, 6, 9, 12 and 24 h). mRNA levels of p21 at 2.1 kb were detected by northern blot hybridization.
Hypophosphorylated pRB associates and inactivates E2F-1, thereby suppressing c-myc gene expression. Since c-myc expression is required for cell proliferation, especially cell-cycle entry from G1 into S phase, the suppression of c-myc expression is considered to be one of the major mechanisms of anti-proliferatory action of 7 -PGA 1 methyl ester. Hitherto at least five different cycline-dependent kinase inhibitors (CKIs) were identified. Figure 5 shows that one such inhibitor, p21 Sdi1/CI P 1/W AF 1 , was specifically induced by 7 -PGA 1 methyl ester in HL-60 cells ( Figure 5 ). This induction was well correlated with the growth inhibition, the accumulation of hypophosphorylated pRB and cell cycle arrest. No induction was detected without the antitumor PG. Moreover, mRNA levels of other CKIs, p27 Kip1 , p16 I NK4A and p18 I NK4C , remained unchanged, and no p15 I NK4B expression was detected in the presence or absence of 7 -PGA 1 methyl ester in HL-60 cells. These observations strongly suggest that the synthetic antitumor PG specifically induces p21 Sdi1/CI P 1/W AF 1 .
The p21 Sdi1/CI P 1/W AF 1 protein binds CDKs and inhibits phosphorylation of pRB by cyclin-CDK complexes, resulting in accumulation of hypophosphorylated pRB (Harper et al., 1993; Xiong et al., 1993) . p21 Sdi1/CI P 1/W AF 1 was shown to be involved in p53-mediated G1 arrest which is related to DNA repair processes after γ -irradiation (El-Dairy et al., 1994; Dulic et al., 1994) . However, since the p53 gene is deleted in HL-60 cells, we conclude that the induction of p21 Sdi1/CI P 1/W AF 1 by the antitumor PG is mediated by a novel process independent of the p53 transcription factor. Moreover, p21 Sdi1/CI P 1/W AF 1 has recently been identified as a DNA synthesis inhibitor in senescent cells. Thus, Figure 6 . Putative pathways of hypophosphorylation of pRB and suppression of c-myc expression triggered by 7 -PGA 1 -mediated induction of p21, as well as GSH conjugation and the subsequent elimination by GS-X pump. The anticancer PG induces de novo synthesis of p21, which is followed by the inhibition of Cdks 2, 4 and 6 and the association of hypophosphorylated pRB with E2F-1, a transcription factor of the c-myc gene. Cyc, cyclin; Cdk, cyclin-dependent kinase.
induction of p21 Sdi1/CI P 1/W AF 1 appears to play a central role in the cell growth inhibition by the antitumor PG (Figure 6 ). Our results are consistent with recent observations reported by Holbrook's research group as well as Stacy and his collabrators (Hitomi et al., 1996) .
Role of MRP/GS-X pump in Cellular Resistance to Antitumor PG
Cell growth inhibition by antitumor PGs is reversible and the reversibility of antitumor action is considered to be due to loss of the reactivity of PGs in the cell . The α,β-unsaturated carbonyl group of antitumor PGs is electrophilic and readily reacts with thiol groups of cellular constitutes, such as GSH, cysteine, and proteins (Honn and Marnett, 1985) . Anticancer PGs with a simple enone group, such as PGA 2 , react with GSH, however the equilibrium favors the GSH adduct formation (Suzuki et al., 1997) . The simple enone PGs are therefore expected to be present in cytoplasm predominantly as biologically inactive GSH adducts. On the other hand, 7 -PGA 1 that possesses a cross-conjugated dienone structure reacts with GSH in a reversible manner but the equilibrium shifts to the free PG to a considerable extent (Suzuki et al., 1997) . In such a case, increased GSH levels are considered to be a major factor to shift the equilibrium of the reaction of 7 -PGA 1 with GSH toward adduct formation. In addition, it is also hypothesized that the resulting GS-PG conjugate is readily exported from cells by the GS-X pump. Overexpression of the MRP/GS-X pump has been found in cisplatin-resistant human leukemia HL-60/R-CP cells . Using HL-60/R-CP cells, we have examined a potential role of the MRP/GS-X pump in cellular resistance to the antitumor PG.
As shown in Figure 2 , proliferation of HL-60/R-CP cells was little affected by 5 µM 7 -PGA 1 methyl Figure 7 . Inhibition of GS-X pump by GIF-0017. GIF-0019 undergoes hydrolysis catalyzed by esterase in the cell. GIF-0017, thus formed, is considered to inhibit the GS-X pump and thereby to enhance cellular accumulation of the anticancer PG, 7 -PGA 1 .
ester. No G1-arrest was observed in the cisplatinresistant cells. c-myc suppression, hypophosphorylation of pRB, and p21 Sdi1/CI P 1/W AF 1 induction in these cells were detected for only a short period (<6 h). Thus, these results suggest that HL-60/R-CP cells, which overexpress the MRP/GS-X pump, are insensitive or resistant to the antitumor PG.
To gain further insight in the role of the MRP/GS-X pump in the cellular resistance, we first examined the reaction of 7 -PGA 1 methyl ester with GSH. The reaction product was identified by reverse-phase high performance liquid chromatography (RP-HPLC) as well as by reverse-phase thin-layer chromatography and NMR. Furthermore, the GSH conjugate of 7 -PGA 1 methyl ester was purified by RP-HPLC, and ATP-dependent transport of the compound was examined using plasma membrane vesicles prepared from HL-60/R-CP cells. ATP-dependent transport of leukotriene C 4 , an endogenous substrate of the MRP/GS-X pump, was competitively inhibited by the GSH conjugate of 7 -PGA 1 methyl ester (IC 50 = 0.75 µM) , suggesting that the GS-conjugate of the antitumor PG is a good substrate for the MRP/GS-X pump. Indeed, plasma membrane vesicles from HL-60/R-CP cells exhibited ATPdependent transport of the GSH adduct of 7 -PGA 1 methyl ester with an apparent K m value of 110 nM. The K m value is comparable to that for leukotriene C 4 .
GIF-0017, a potent GS-X pump inhibotor synthesized in our group (Furuta, Ishikawa, and Suzuki, manuscript in preparation), effectively inhibited the transport of the GS-PG conjugate in plasma membrane vesicles prepared from HL-60/R-CP cells. GIF-0019, a derivative of GIF-0017 modified to penetrate cell membrane, elicited cellular sensitivity of HL-60/R-CP cells to 7 -PGA 1 methyl ester. 10 µM GIF-0019 inhibited cell proliferation of HL-60/R-CP cells in the presence of 7 -PGA 1 methyl ester over 100 h. This suggests that GIF-0019 readily undergoes hydrolysis catalyzed by esterase in the cell to form GIF-0017, which blocks the GS-X pump for the extrusion of the GS-PG conjugate from the cell (Figure 7) . Because of the reversible reaction between GSH and 7 -PGA 1 , the free active form of the PG can be formed from its Figure 8 . Detection of MRP1 and γ -GCS mRNA in different cancer cell lines by RNase protection assay. Experimental details and methods are described in Kuo et al., 1997. GSH adduct. The GS-X pump is considered to play a significant role in reducing accumulation of 7 -PGA 1 in the cell, thereby modulating the antiproliferative activity of the anticancer PG.
Coordinated Expression of γ -GCS and MRP/GS-X Pump
At present, little is known about the regulation of the expression of the MRP/GS-X pump gene. Our group has recently demonstrated that MRP1 and γ -GCS genes are coordinately induced by cisplatin and heavy metals, such as arsenite, cadmium, and zinc in cisplatin-resistant HL-60/R-CP cells . To extend the study, we analyzed the levels of MRP and γ -GCS mRNA in small-cell lung cancer cells and their drug-resistant variants, i.e., SR2 (cisplatin-resistant) as well as SR2A and SR3A (doxorubicin-resistant). There was a clear correlation between the levels of MRP1 and γ -GCS mRNA expression (Kuo et al., 1997) . Furthermore, human glioma A172 cells pretreated with 1-[5-(4-amino-2-methyl)pyrimidyl]methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU) for 24 h enhanced mRNA levels of both MRP1 and γ -GCS by 3-to 5-fold (Gomi et al., 1997) , suggesting that expression of MRP1 gene is closely related with cellular GSH biosynthesis and that certain common factor(s) may regulate the expression of both MRP1 and γ -GCS genes.
We further examined coordinated expression of MRP1 and γ -GCS mRNA in drug-sensitive tumor cell lines (Figure 8 ). We randomly chose 17 cell lines: three breast cancer (MDA-MB-468, MDA-MB-453, and MDA-MB-361), three glioma (U251, D54, and T98), three small-cell lung cancer SCOG) , two pancreas cancer (PANC3 and BXPC3), two leukemia (pre-B and T-ALL), one prostate cancer (PC3), one ovarian cancer (SK-OV-3), one hepatoma (HepG2) and one colon cancer (HT29). Substantial variations in MRP1 and γ -GCS mRNA levels were observed in those tumor cell lines. Cell lines expressing low levels of MRP1 and γ -GCS mRNA include PC3, H-226, T-ALL and MDA-MB-468; and those with high levels include PAN3, HT-29, BXPC3, T98, MDA-MB361, and pre-B cells. When the levels of MRP1 mRNA were plotted against those of γ -GCS mRNA, a correlation coefficient of 0.861 was obtained (Kuo et al., 1997) . These results suggest that, even in drug-sensitive tumor cells, there was a good correlation between the levels of MRP1 and γ -GCS mRNA expression.
The fact that MRP1 and γ -GCS can be coordinately induced by cisplatin, ACNU, and heavy metals provides important information to our understanding of how drug resistance genes are acutely induced upon drug treatments. Since cis-regulatory elements including AP-l binding sites have been identified in the promoter regions of human γ -GCS and MRP1 genes (Mulcahy and Gipp, 1995; Yao et al., 1995; Zhu and Center, 1994) (Figure 9 ), it is extremely interesting to examine whether AP-1 is responsible for the transcriptional regulation of the expression of MRP1 and γ -GCS genes in cancer cells. Unlike cell culture studies where drug-resistant variants are usually obtained through continuous drug exposure, such transient induction of drug-resistance gene expression Figure 9 . Potential regulation sites in the promotor regions of human MRP1 and γ -GCS genes. CRE, cyclic AMP response element; ERE, estrogen response element; GRE glucocorticoide response element, XRE, xenobiotic response elements, EpRE, Electrphile response element; CAT box, CCAAT box. Data from Zhu and Center, 1994; Yao et al., 1995; Mulcahy and Gipp, 1995. is more directly related to cancer chemotherapeutic protocols. Interestingly, human colorectal cancers frequently overexpress MRP1 and γ -GCS genes . Because patients involved in the study had not been treated with chemotherapeutic agents, it is suggested that up-regulation of different drug resistance genes is associated with different human cancers and, more importantly, development of drug resistance in these cancers is an intrinsic mechanism. Because intrinsic drug resistance is the major factor controlling efficacy of chemotherapy in cancer treatment, a better understanding of how different drug-resistance genes are regulated in different tumor systems is of great importance for development of effective strategies to circumvent drug resistance in cancer chemotherapy.
Importance of Posttranscriptional Regulation
Emerging evidence in the recent years has indicated that posttranscriptional regulation plays an important role in the modulation of drug-resistance gene expression in cells treated with various cytotoxic substances and under various physiological conditions (Chin et al., 1990; Chaudhary and Roninson, 1993) . For example, steady state levels of MDR mRNA encoding P-glycoprotein can be transiently induced in cultured cells by many chemotherapeutic agents (Chin et al., 1990; Chaudhary and Roninson, 1993) . Although transcriptional regulation has been noted, posttranscriptional regulation is primarily responsible for the observed increases of MDR mRNA. Inhibition of protein synthesis by cycloheximide could also enhance the steady state level of MDR mRNA in cultured cells (Gant et al., 1992; Fardel et al., 1993) . Although an initial report suggested that the enhancement was due to increased transcriptional rate (Gant et al., 1992) , recent reports have demonstrated that posttranscriptional control is primarily responsible (Schuetz et al., 1995; Kren and Steer, 1996) . In experimental animal models, posttranscriptional regulation was observed for the upregulation of mdr gene expression during partial hepatectomy (Chin et al., 1990) and in the uterine epithelial cells during pregnancy (Kuo et al., 1995) . Thus, there may be overlapping mechanisms that control P-glycoprotein and MRP/GS-X pump expression. It would be of interest to determine whether similar mechanisms are involved in the increased mRNA levels of MRP1 and γ -GCS in vivo as well as in vitro.
It remains critically important to determine whether MRP1 and γ -GCS mRNA levels are transiently elevated during chemotherapy in clinical set-tings, and if so, whether the induction is controlled by posttrancriptional or transcriptional events. Our most recent study has demonstrated that MRP1 and γ -GCS were transiently induced by ACNU and cycloheximide, and that the upregulation of the expression of these genes was controlled at the posttranscriptional levels (Gomi et al., 1997) . While cis-acting elements for transcriptional regulation of MRP1 (Zhu and Center, 1994 ) and γ -GCS (Mulcahy et al., 1997) have recently been identified, little is known about molecular details regarding posttranscriptional control for these genes. A better understanding of how MRP and γ -GCS genes are upregulated under various enviromental influences as well as how γ -GCS is actually involved in the MRP-mediated drug resistance, might provide valuable insights into molecular mechanisms underlying the clinical problems of drug resistance in cancer chemotherapy.
